UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 6, 2017
IMMUNE PHARMACEUTICALS INC.
(Exact name of Registrant as Specified in its Charter)
Delaware | 001-36602 | 52-1841431 | ||
(State or other jurisdiction of incorporation or organization) |
(Commission File Number) |
(I.R.S. Employer Identification No.) |
550 Sylvan Avenue, Suite 101, Englewood Cliffs, NJ | 07632 |
(Address of Principal Executive Offices) | (Zip Code) |
(201) 464-2677
Registrant’s telephone number, including area code
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2-(b)) |
¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 5.02. | Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
On June 6, 2017, Dr. Monica Luchi provided the Board of Directors (the “Board”) of Immune Pharmaceuticals Inc. (the “Company”) with notice of her resignation from the Company as Chief Medical Officer, and President, Inflammatory Disease and Dermatology Division.
Dr. Luchi has agreed to assist the Company in planning her transition and addressing clinical study and medical affairs matters as needed until such time that a suitable individual is identified to assume those responsibilities.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
IMMUNE PHARMACEUTICALS, INC. | ||
By: | /s/ Elliot Maza | |
Name: | Elliott Maza | |
Title: | Interim Chief Executive Officer |
Date: June 12, 2017